Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study investigated the efficacy and safety of insulin degludec (IDeg) once daily (OD), varying injection timing day to day in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, open-label, treat-to-target, noninferiority trial compared IDeg forced flexible (Forced-Flex) OD (given in a fixed schedule with a minimum 8 and maximum 40 hours between doses) with IDeg or insulin glargine (IGlar) given at the same time daily OD. In the 26-week extension, all IDeg subjects were transferred to a free-flexible (Free-Flex) regimen, which allowed any-time-of-day dosing, and compared with subjects continued on IGlar. RESULTS: After 26 treatment weeks, mean glycosylated hemoglobin was reduced with IDeg Forced- Flex (-0.40%), IDeg (-0.41%), and IGlar (-0.58%). IDeg Forced-Flex noninferiority was achieved. Fasting plasma glucose reductions were similar with IDeg Forced-Flex and IGlar but greater with IDeg (-2.54 mmol/L) than IDeg Forced-Flex (-1.28 mmol/L) (P = .021). At week 52, IDeg Free-Flex subjects had similar glycosylated hemoglobin but greater fasting plasma glucose reductions than IGlar subjects (-1.07 mmol/L) (P = .005). Confirmed hypoglycemia rates (plasma glucose <3.1 mmol/L or severe hypoglycemia) were similar at weeks 26 and 52. Nocturnal confirmed hypoglycemia was lower with IDeg Forced-Flex vs IDeg (37%; P = .003) and IGlar (40%; P = .001) at week 26 and 25% lower with IDeg Free-Flex vs IGlar (P = .026) at week 52. CONCLUSIONS: IDeg can be administered OD at any time of day, with injection timing varied without compromising glycemic control or safety vs same-time-daily IDeg or IGlar. This may improve basal insulin adherence by allowing injection-time adjustment according to individual needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a result of the treat-to-target design, a comparison can be made in terms of differences in endpoints such as hypoglycaemia (but not, for example, HbA1c), as illustrated in Table 4 [48–54].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of the phase III trials with IDeg were designed as treat-to-target trials striving for an ambitious (fasting) blood glucose level target of 4–5 mmol/L (70–90 mg/dL).”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the studies showed that there was no apparent association between the development of cross-reacting antibodies and hypoglycaemia, HbA1c or insulin dose [48, 49, 53].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The studies found that, even with such extreme dosing windows, glycaemic control and safety with IDeg were not compromised in comparison to the subjects receiving IDeg or IGlar once daily always at the same time of day [49, 53].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“two treat-to-target, randomised studies where extreme dosing intervals of 8–40 h were used in subjects with T1DM and T2DM over a treatment duration of 26–52 weeks [49, 53].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [49]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Ethical principles for medical research involving human subjects
(2003) · Manual for Research Ethics Committees · doi:10.1017/cbo9780511550089.027 · Cited by 2,585
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
(2014) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jwiet-2014-0117 · Cited by 2,473
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
World Medical Association (WMA) (2009) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/9783110208856.233 · Cited by 1,087
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 1×
“fected by perceived burden of therapy (1, 6).”
BackgroundMire-Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.06.002 · Cited by 624 · cited 1×
“Antibody analyses were performed at Celerion Switzerland AG (Fehraltorf, Switzerland), using a validated RIA method (14, 15).”
MethodSection XXIV. Partition Chromatographs
(2009) · Biotechnology · doi:10.1201/9781420084498-31 · Cited by 590
Research works printed but not linked: 5
- Anderson, 2003, Self-reported compliance with insulin injection therapy in subjects with type 1 and type 2 diabetes, Diabetes Metab, 29, A275
- Jonassen, 2010, Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation, Diabetes, 59, A11
- Heise, 2011, Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine, Diabetes, 60, LB11
- Lantus, 2007, Lantus package insert
- Heise, 2011, The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state, Diabetes, 60, A263
Cited by
Insulin analogues in type 1 diabetes mellitus: Getting better all the time
Mathieu, C., Gillard, P., & Benhalima, K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.39 · Cited by 248
Self-citationA Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226
“The studies found that, even with such extreme dosing windows, glycaemic control and safety with IDeg were not compromised in comparison to the subjects receiving IDeg or IGlar once daily always at the same time of day [49, 53].”
BackgroundMethodInfluentialDanne, T., Phillip, M., Buckingham, B. A., Jarosz-Chobot, P., Saboo, B., Urakami, T., Battelino, T., Hanas, R., & Codner, E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12718 · Cited by 225
Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
Janež, A., Guja, C., Mitrakou, A., Lalic, N., Tankova, T., Czupryniak, L., Tabák, A. G., Prazny, M., Martinka, E., & Smircic-Duvnjak, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00743-7 · Cited by 177
Weight management in patients with type 1 diabetes and obesity
Mottalib, A., Kasetty, M., Mar, J. Y., Elseaidy, T., Ashrafzadeh, S., & Hamdy, O. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0918-8 · Cited by 149
Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0157-z · Cited by 135
“[31] had the highest rates of hypoglycemia (across all categories) and the lowest end-of-trial HbA1c levels, at week 26.”
BackgroundRussell-Jones, D., Babazono, T., Cailleteau, R., Engberg, S., Irace, C., Kjaersgaard, M. I. S., Mathieu, C., Rosenstock, J., Woo, V., & Klonoff, D. C. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02179-7 · Cited by 115
“16 Furthermore, despite the higher number of severe hypoglycaemic episodes in the icodec group, the incidence was low in both groups and management of severe hypoglycaemic episodes did not differ between icodec and the daily insulin comparator, with most episodes only requiring oral carbohydrate…”
BackgroundSelf-citationHeise, T., & Mathieu, C. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12782 · Cited by 106
Self-citationBasal insulin analogues in the management of diabetes mellitus: what progress have we made?
Owens, D. R., Matfin, G., & Monnier, L. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2469 · Cited by 108
Vora, J., Christensen, T., Rana, A., & Bain, S. C. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0076-9 · Cited by 96
“001) [9] and in the BEGIN Flex T1 trial (statistical significance not reported) [10]; and”
BackgroundMethodResultInfluentialSelf-citationBailey, T. S., Pettus, J., Roussel, R., Schmider, W., Maroccia, M., Nassr, N., Klein, O., Bolli, G. B., & Dahmen, R. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.10.001 · Cited by 94
Cengiz, E., Danne, T., Ahmad, T., Ayyavoo, A., Beran, D., Ehtisham, S., Fairchild, J., Jarosz‐Chobot, P., Ng, S. M., Paterson, M., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13442 · Cited by 93
“can be given once a day at any time of the day as long as 8 h has elapsed since the previous injection.(54)”
BackgroundThalange, N., Deeb, L., Iotova, V., Kawamura, T., Klingensmith, G., Philotheou, A., Silverstein, J., Tumini, S., Ocampo Francisco, A., Kinduryte, O., et al. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12263 · Cited by 91
“Furthermore, although not formally tested in this study, flexibility in administration timing of IDeg was shown to be possible without compromising glycemic control in adults (20, 21).”
BackgroundHome, P. D. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12501 · Cited by 90
“This is confirmed by studies of extreme flexibility of injection times, which show no major detriment [75].”
BackgroundKorsatko, S., Deller, S., Koehler, G., Mader, J. K., Neubauer, K., Adrian, C. L., Thomsen, H., Haahr, H., & Pieber, T. R. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0096-7 · Cited by 89
Matsuhisa, M., Koyama, M., Cheng, X., Takahashi, Y., Riddle, M. C., Bolli, G. B., Hirose, T., & on behalf of the EDITION JP 1 study group (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12619 · Cited by 85
“This is similar to results observed in two studies comparing Gla-100 and insulin degludec in multinational populations, which have also indicated no differences in HbA1c reduction between treatments [24,25].”
ResultThe past, present, and future of basal insulins
Pettus, J., Santos Cavaiola, T., Tamborlane, W. V., & Edelman, S. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2763 · Cited by 80
“degludec and fixed dosing with insulin glargine 100 units/mL; however, rates of nocturnal confirmed hypoglycaemia were lower with insulin degludec [124].”
BackgroundMoon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Severe hypoglycaemia in adults with insulin‐treated diabetes: impact on healthcare resources
Heller, S. R., Frier, B. M., Hersløv, M. L., Gundgaard, J., & Gough, S. C. L. (2016) · Diabetic Medicine · doi:10.1111/dme.12844 · Cited by 74
Clinical use of insulin degludec
Vora, J., Cariou, B., Evans, M., Gross, J. L., Harris, S., Landstedt-Hallin, L., Mithal, A., Rodriguez, M. R., & Meneghini, L. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.002 · Cited by 73
“In the T1DM trials included in the meta-analysis [46,47] there”
BackgroundResultInfluentialThe risks of nocturnal hypoglycaemia in insulin-treated diabetes
Graveling, A. J., & Frier, B. M. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.012 · Cited by 85
Gallo, M., Muscogiuri, G., Felicetti, F. C., Faggiano, A., Trimarchi, F., Arvat, E., Vigneri, R., & Colao, A. (2017) · Metabolism · doi:10.1016/j.metabol.2017.09.013 · Cited by 76
Russell-Jones, D., Gall, M.-A., Niemeyer, M., Diamant, M., & Del Prato, S. (2015) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.06.005 · Cited by 66
“The reduced risk of nocturnal hypoglycaemia and better FPG observed with IDeg may result in additional positive features of this long-acting insulin analogue, including greater flexibility as supported by the ‘forced flexible’ dosing regimen showing that glycaemic control and safety were not compromised when IDeg was…”
BackgroundSelf-citationRecent Advances in Insulin Therapy
Wilson, L. M., & Castle, J. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0065 · Cited by 64
“Hepatic-directed insulin lispro (Diasome Pharmaceuticals, Inc.) is a subcutaneously delivered formulation that uses a hepatocyte targeting moiety, biotin-phosphatidylethanolamine in a phospholipid matrix, which passively binds *100 insulin molecules.69 A recently completed 26-week, multicenter randomized, doubleblinde…”
BackgroundInfluentialConcentrated insulins: the new basal insulins
Davis, S. N., Lamos, E. M., & Younk, L. M. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s99855 · Cited by 61
“Insulin degludec and glargine U300 have been tested with alternate dosing schemes (as opposed to fixed morning or evening administration).(37,48) Degludec U100 was tested using a minimum of 8 hours and a maximum of 40 hours between doses, and glargine U300 was tested every 24 hours ± 3 hours.”
Sorli, C., Warren, M., Oyer, D., Mersebach, H., Johansen, T., & Gough, S. C. L. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0128-2 · Cited by 54
“Two trials (T1DM Trial 3770 and T2DM Trial 3668) included an additional dosing arm, in which the extremes of once-daily dosing of IDeg were tested by alternating morning and evening dosing from day to day [23, 24].”
BackgroundBiester, T., Blaesig, S., Remus, K., Aschemeier, B., Kordonouri, O., Granhall, C., Søndergaard, F., Kristensen, N. R., Haahr, H., & Danne, T. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12116 · Cited by 53
Davies, M. J., Gross, J. L., Ono, Y., Sasaki, T., Bantwal, G., Gall, M. A., Niemeyer, M., Seino, H., & on behalf of the BEGIN BB T1 study group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12298 · Cited by 53
Little, S. A., Leelarathna, L., Barendse, S. M., Walkinshaw, E., Tan, H. K., Lubina Solomon, A., de Zoysa, N., Rogers, H., Choudhary, P., Amiel, S. A., et al. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2492 · Cited by 48
Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls
Pedersen‐Bjergaard, U., & Thorsteinsson, B. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0965-1 · Cited by 52
Zhang, X.-W., Zhang, X.-L., Xu, B., & Kang, L.-N. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1107-1 · Cited by 44
Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0051-1 · Cited by 46
“A second randomized, open-label, multicentre, phase III trial of 26 weeks duration (BEGIN Flex T1) examined the use of flexible dosing with insulin degludec in adult patients with type 1 diabetes [37].”
BackgroundMethodInfluentialHeise, T., Kaplan, K., & Haahr, H. L. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817731422 · Cited by 40
Evans, M., Wolden, M. L., Gundgaard, J., Chubb, B., & Christensen, T. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.971160 · Cited by 41
“observed a mean basal insulin dose reduction of 14% with IDeg at end-of-trial, as well as bolus and total insulin dose reductions of 10% and 11%, respectively (all statistically significant); and Mathieu et al.(19) reported that mean basal, bolus, and total insulin doses were 4%, 18%, and 11% lower, respectively, in t…”
BackgroundGoldman, J., Kapitza, C., Pettus, J., & Heise, T. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1335192 · Cited by 38
“Studies in patients with T1D and T2D showed that the injection time of insulin degludec could be varied without compromising either glycemic control or safety compared with same-time administration of insulin degludec [83, 94].”
BackgroundKang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus
Hemmingsen, B., Metzendorf, M.-I., & Richter, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013498.pub2 · Cited by 37
Freemantle, N., Evans, M., Christensen, T., Wolden, M. L., & Bjørner, J. B. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12086 · Cited by 34
Glycemic Management in Adults With Type 1 Diabetes
McGibbon, A., Adams, L., Ingersoll, K. S., Kader, T., & Tugwell, B. D. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.012 · Cited by 58
Degludec: the new ultra-long insulin analogue
Tambascia, M. A., & Eliaschewitz, F. G. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0037-0 · Cited by 41
“026) [19].”
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
Kalra, S. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0067-x · Cited by 35
“various oral antihyperglycemic drugs [15].”
Heller, S., Mathieu, C., Kapur, R., Wolden, M. L., & Zinman, B. (2016) · Diabetic Medicine · doi:10.1111/dme.13002 · Cited by 34
Self-citationDżygało, K., Golicki, D., Kowalska, A., & Szypowska, A. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0604-0 · Cited by 35
Will the next generation of basal insulins offer clinical advantages?
Garber, A. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12219 · Cited by 33
“After 26 weeks, 239 patients randomized to the two insulin degludec groups continued on insulin degludec using a ‘free flexible’ regimen, in which the injection could be taken at any time of day provided the dose intervals remained between 8 and 40 h [40].”
BackgroundMethodLiu, W., Yang, X., & Huang, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8726046 · Cited by 32
“Five studies recruited patients with T1DM [11, 14, 22, 25, 26], and the other ten studies enrolled patients with T2DM [10, 12, 13, 16–18, 20, 21, 23, 24].”
ResultNew Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Standl, E., & Owen, D. R. (2016) · Diabetes Care · doi:10.2337/dcs15-3011 · Cited by 35
“cacy at peripheral muscle and adipose tissues, as might be evidenced by increased lipolysis and some loss of body weight (19,50,51,57).”
BackgroundTricco, A. C., Ashoor, H. M., Antony, J., Bouck, Z., Rodrigues, M., Pham, B., Khan, P. A., Nincic, V., Darvesh, N., Yazdi, F., et al. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06642-7 · Cited by 38
Setty, S. G., Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133716 · Cited by 37
New Developments in Insulin Therapy for Type 2 Diabetes
SORLI, C. H. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.006 · Cited by 34
Kusunoki, Y., Katsuno, T., Miyakoshi, K., Ikawa, T., Nakae, R., Ochi, F., Tokuda, M., Akagami, T., Murai, K., Miuchi, M., et al. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0048-5 · Cited by 28
“Previous studies compared insulin degludec with insulin glargine or detemir and showed that glycemic control was similar, but the frequency of nocturnal hypoglycemia was lower in the degludec group [18–23].”
ResultEvans, M., McEwan, P. C., & FOOS, V. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.975234 · Cited by 30
Insulinoterapia no diabetes mellitus tipo 1 (DM1)
Júnior, W. S. D. S., Gabbay, M. A. L., Lamounier, R. N., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-5 · Cited by 59
Weight Management in Patients with Type 2 Diabetes: a Multidisciplinary Real-world Approach
Hamdy, O., Ashrafzadeh, S., & Mottalib, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1030-4 · Cited by 30
Insulin discovery: A pivotal point in medical history
Falcetta, P., Aragona, M., Bertolotto, A., Bianchi, C., Campi, F., Garofolo, M., & Prato, S. D. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154941 · Cited by 33
Aso, Y., Suzuki, K., Chiba, Y., Sato, M., Fujita, N., Takada, Y., Murano, S., & Kuroda, H. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.06.007 · Cited by 29
“12 with treatment, because IDeg offers a more flexible dosing interval to accommodate various lifestyles (17, 18).”
BackgroundLucidi, P., Candeloro, P., Cioli, P., Andreoli, A. M., Pascucci, C., Gambelunghe, A., Bolli, G. B., Fanelli, C. G., & Porcellati, F. (2020) · Diabetes Care · doi:10.2337/dc20-1033 · Cited by 30
Flexibly timed once‐daily dosing with degludec: a new ultra‐long‐acting basal insulin
Josse, R. G., & Woo, V. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12114 · Cited by 24
“[38] transitioned patients from the two degludec arms to an ad lib daily-dosing regimen and compared these patients with others who maintained oncedaily glargine for the full 52 weeks.”
BackgroundMethodInfluentialWoo, V. C. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.007 · Cited by 23
Holmes, R. S., Crabtree, E. A., & McDonagh, M. S. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13614 · Cited by 24
New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice
Bolli, G. B., & DeVries, J. H. (2015) · Diabetes Care · doi:10.2337/dc14-2314 · Cited by 28
Injectable systems for long-lasting insulin therapy
Niloy, K. K., & Lowe, T. L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115121 · Cited by 25
Patient safety and minimizing risk with insulin administration – role of insulin degludec
Atkin, S. L., & Aye, M. (2014) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s59566 · Cited by 31
Yamamoto, K., Miyoshi, H., Fujiwara, Y., Kameda, R., Ichiyama, M., Nomoto, H., Kameda, H., Nakamura, A., & Atsumi, T. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0438 · Cited by 22
“In a phase 3 clinical trial, Deg decreased the frequency of nocturnal hypoglycemia compared to Gla [6-8].”
MethodInfluentialClinical use of insulin degludec: Practical experience and pragmatic suggestions
Kalra, S., & Gupta, Y. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.153918 · Cited by 22
Treating obesity in type 1 diabetes mellitus – review of efficacy and safety
Freeby, M., & Lane, K. L. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000841 · Cited by 23
Rossetti, P., Ampudia‐Blasco, F. J., & Ascaso, J. F. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12256 · Cited by 20
“The fact that this reduction was also obtained when intervals between injections were significantly different from 24 h [74] is an indirect confirmation of the positive effects of degludec’s ultra-long duration of action and reduced intra-subject variability.”
BackgroundWarren, M., CHAYKIN, L. B., Jabbour, S. A., Sheikh‐Ali, M., Hansen, C. T., Nielsen, T. S. S., & Norwood, P. C. (2017) · Clinical Diabetes · doi:10.2337/cd15-0058 · Cited by 20
Shimoda, S., Sato, M., Sekigami, T., Motoshima, H., Yoshimura, R., Fukuda, K., Matsuo, Y., Noda, H., Okubo, M., Ichimori, S., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12496 · Cited by 19
Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
Miccoli, R., Dardano, A., Bianchi, C., & Prato, S. D. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s40097 · Cited by 19
EINHORN, D. F., Handelsman, Y., Bode, B. W., Endahl, L. A., Mersebach, H., & King, A. B. (2015) · Endocrine Practice · doi:10.4158/ep14523.or · Cited by 18
Cengiz, E., Danne, T., Ahmad, T., Ayyavoo, A., Beran, D., Codner, E., Ehtisham, S., Jarosz-Chobot, P., Mungai, L. N. W., Ng, S. M., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000543169 · Cited by 17
Concepts and clinical use of ultra-long basal insulin
Eliaschewitz, F. G., & Barreto, T. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0117-1 · Cited by 20
“Insulin degludec in the flexible schedule achieved non-inferiority and significantly reduced confirmed nocturnal hypoglycemia [31].”
BackgroundPollock, R. F., & Tikkanen, C. K. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1245663 · Cited by 20
Drab, S. R., & Philis‐Tsimikas, A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1361 · Cited by 18
the RESTORE-1 Study Group, Laviola, L., Porcellati, F., Bruttomesso, D., Larosa, M., Rossi, M. C., & Nicolucci, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00982-z · Cited by 16
Minimising hypoglycaemia in the real world: the challenge of insulin
Mathieu, C. (2021) · Diabetologia · doi:10.1007/s00125-020-05354-7 · Cited by 16
“Another advantage of these very-long-acting insulin analogues, in particular insulin degludec, is the increased flexibility in the time of injection, again contributing to improved quality of life [32].”
BackgroundSelf-citationPfützner, A., Forst, T. M., Niemeyer, M., & Bailey, T. S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.927438 · Cited by 17
“Among other insulin analogues, FT is used to deliver the basal insulin, insulin degludec (IDeg) [13-16], a novel basal insulin, characterized by an ultra-long duration of action, allowing for flexibility in dose timing of once daily injections.”
MethodClinical use of the co-formulation of insulin degludec and insulin aspart
Kumar, A., Awata, T., Bain, S. C., Ceriello, A., Fulcher, G. R., Unnikrishnan, A., Arechavaleta, R., González-Gálvez, G., Hirose, T., Home, P., et al. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12821 · Cited by 17
Self-citationType 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges
Blumer, I. R., & CLEMENT, M. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.020 · Cited by 18
“Presently, NPH, detemir, and glargine 100 U/mL are usually titrated daily to a targeted fasting glucose concentration, but in the trials of the long-acting basal insulin analogues, titration was performed from every 3 to 4 days (glargine 300 U/mL) up to once weekly.(8,57,58,62,63) Although minimizing the risk for hypo…”
BackgroundInsulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
Lindauer, K., & Becker, R. H. A. (2018) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp203269 · Cited by 18
“The modeling and simulation methods implemented here could be useful in predicting how changes in a basal insulin regimen (such as changing the interval be-tween daily injections or switching from one insulin glargine product to the other) may affect PK profiles.”
Lefever, E., Vliebergh, J., & Mathieu, C. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1856813 · Cited by 17
Self-citationAdvances in newer basal and bolus insulins: impact on type 1 diabetes
Vliebergh, J., Lefever, E., & Mathieu, C. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000599 · Cited by 18
“This gives the patient the opportunity to adjust the timing of injection in according to their individual schedule [36].”
BackgroundSelf-citationInsulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
Kalra, S. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0047-6 · Cited by 18
Management of severe insulin resistance in patients with type 1 diabetes
Schechter, R., & Reutrakul, S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0641-2 · Cited by 15
Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy
Kumar, A. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.904851 · Cited by 17
“This in turn improves adherence and acceptance of basal insulin therapy in patients with diabetes [32,33].”
BackgroundBiester, T., Danne, T., Bläsig, S., Remus, K., Aschemeier, B., Kordonouri, O., Bardtrum, L., & Haahr, H. L. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12358 · Cited by 15
“with type 1 diabetes (30), IDeg may be suited for”
BackgroundBohn, B., Zimmermann, A., Wagner, C., Merger, S. R., Dunstheimer, D., Kopp, F., Gollisch, K. S. C., Zindel, V., & Holl, R. W. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.031 · Cited by 15
Woo, V. C., Berard, L., & Roscoe, R. S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00915-w · Cited by 17
Estremera, E., Cabrera, A., Beneyto, A., & Vehí, J. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104141 · Cited by 20
Kobuke, K., Yoneda, M., Nakanishi, S., Ohno, H., Maeda, S., & Egusa, G. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12373 · Cited by 16
Lajara, R., Cengiz, E., & Tanenberg, R. J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1298522 · Cited by 15
Dawoud, D., O’Mahony, R., Wonderling, D. E., Cobb, J. K., Higgins, B. G., & Amiel, S. A. (2017) · Value in Health · doi:10.1016/j.jval.2017.04.024 · Cited by 18
Glastras, S. J., Cohen, N. D., Dover, T., Kilov, G., MacIsaac, R. J., McGill, M. J., & Fulcher, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041091 · Cited by 17
“Importantly, dose timing can be flexible from day to day (within 8–40 h of the previous dose with once-daily (OD) dosing) [37].”
BackgroundKadowaki, T., Jinnouchi, H., Kaku, K., Hersløv, M. L., Hyllested-Winge, J. L., & Nakamura, S. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12502 · Cited by 15
Cardiovascular effects of basal insulins
Mannucci, E., Giannini, S., & Dicembrini, I. (2015) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s43300 · Cited by 15
Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus
Frier, B. M., Ratzki‐Leewing, A. A., & Harris, S. B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13732 · Cited by 12
New risk and protective factors for severe hypoglycaemia in people with type 1 diabetes
Wohland, T., Holstein, J. D., Patzer, O. M., Mende, M., Tiemann, T., Koch-Tessarek, C., Kovacs, P. L., & Holstein, A. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.12.006 · Cited by 14
Suzuki, J., Yamakawa, T., Oba, M., Nagakura, J., Shigematsu, E., Tamura, H., Takahashi, K., Okamoto, Y., Sakamoto, R., Shinoda, M., et al. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0309 · Cited by 13
Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice
Davis, C. S., Fleming, J. W., Malinowski, S. S., Brown, M. A., & Fleming, L. W. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000076 · Cited by 17
Segal, A. R., Vootla, T., & Beaser, R. S. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.009 · Cited by 14
Metadata
- Authors
- Mathieu, C., Hollander, P., Miranda-Palma, B., Cooper, J., Franek, E., Russell-Jones, D., Larsen, J., Tamer, S. C., Bain, S. C., & on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Baylor University Medical Center (US)
- University of Miami (US)
- Stavanger University Hospital (NO)
- Central Clinical Hospital (PL)
- Royal Surrey County Hospital (GB)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S (J.L., S.C.T.), DK-2860 Søborg, Denmark
- Swansea University (GB)
- Corresponding author
- Mathieu, Chantal
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-03-01
- Volume
- 98
- Issue
- 3
- Pages
- 1154-1162
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3612802
- OpenAlex
- W2044617125
- Semantic Scholar
- 5d22f297ac5f19579d628d305c28db5f36165eaf
- Cited by
- 219
- References
- 25
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 5 · 2023: 11 · 2022: 11 · 2021: 12 · 2020: 10 · 2019: 11 · 2018: 19 · 2017: 27 · 2016: 24 · 2015: 27 · 2014: 29 · 2013: 24
- FWCI
- 27.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Cardiff University
- European Foundation for the Study of Diabetes
- Novo Nordisk
- Servier
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- insulin degludec, insulin glargine, type 1 diabetes, basal insulin, flexible dosing, injection timing, HbA1c, fasting blood glucose, hypoglycemia, nocturnal hypoglycemia, insulin adherence, basal insulin therapy, non-inferiority, glycemic control, long-acting insulin analogues
- MeSH terms
- Insulin Glargine, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Self Administration, Treatment Outcome, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.